Navigation Links
Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
Date:9/22/2008

this important milestone, the dosing of our first patient. Along with our strategic partner and contract research organization, Cato Research Ltd., we continue to be extremely focused on enrolling appropriate patients and initiating new sites to meet our corporate goals," stated Dr. Juliet Singh, President and Chief Executive Officer of Transdel Pharmaceuticals. "Ketotransdel(TM) could address a significant unmet medical need for patients and physicians seeking a potentially safer effective pain alternative to existing pain management approaches, such as oral NSAIDs. We are committed to aggressively advancing this program to fulfill this unmet medical need."

Ketotransdel(TM) which consists of an elegant cream formulation is designed to be applied directly to the site of the pain. It is absorbed within minutes and is not associated with the limitations of patches. Musculoskeletal pain conditions are defined as pain that affects the muscles, ligaments and tendons. If approved, Ketotransdel(TM) could be the first topical cream in the United States for treatment of acute pain related to musculoskeletal conditions.

Industry estimates indicate that the market for NSAIDs and Cox-2 inhibitors exceeds $6 billion per year and that more than 30 million people worldwide use NSAIDs daily. Due to the recognition of known risks associated with orally administered NSAIDs, including cardiovascular, gastrointestinal and other medical complications, and the decline in the use of Cox-2 inhibitors due to safety concerns, the Company believes that there is a significant demand for topical pain management products such as Ketotransdel(TM).

If and when the FDA approves Ketotransdel(TM) for treatment of acute pain, the Company intends to pursue FDA approval of Ketotransdel(TM) for other indications, such as osteoarthritis. The Company believes that the clinical success of Ketotransdel(TM) will facilitate the use of the Transdel(TM) delivery technology, which is utilize
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
3. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
4. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
7. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
(Date:9/30/2014)... LEXINGTON, Ky. , Sept. 30, 2014 ... coherence tomography (OCT), offered a new look at the ... to alter how physicians understand and treat the disease, ... study, conducted at Baptist Health Lexington between September 2010 ... issue of the Journal of the American College ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... , , VENLO, Netherlands , Feb. 2 QIAGEN N.V. ... financial results call. The Webcast will take place at 9:30 a.m. EST on ... President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer. , ... QIAGEN,s fourth quarter and year-end 2009 financial , ...
... , JERUSALEM , Feb. ... ) announced today the availability of new resources to support ... to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] brand ... due to inadequate secretion of normal endogenous growth hormone. The ...
Cached Medicine Technology:Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 2Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 2Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 4Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 5Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 6
(Date:10/1/2014)... This October, Request A Test , a leading ... 10% off all testing for Diabetes . Customers ... save. The Center for Disease Control (CDC) reports that ... Diabetes. Because many people do not display symptoms, it ... serious health problems. Blood testing can help a person ...
(Date:10/1/2014)... October 01, 2014 After a run ... "Beautiful Births", emerging filmmaker Jacqui Blue is continuing her ... discover the truth about natural birth. The documentary has ... over the world and has been an effective medium ... the topics highlighted in the film provide a wealth ...
(Date:10/1/2014)... 01, 2014 The Oliver Law ... new Other-Sonic Ultrasound Gel lawsuit web page ... the litigation surrounding the 2011 Pseudomonas aeruginosa / ... Royal Oak, Michigan, which was ultimately traced to ... representing William Beaumont patients who allegedly became ill ...
(Date:10/1/2014)... October 01, 2014 Indosoft, Inc., a leading ... announces that it has added support for Sangoma Lyra ... and Indosoft have a history of bringing innovative ... patent-pending technology offers a significant benefit to those using Asterisk ... is now available to users of Q-Suite. , In the ...
(Date:10/1/2014)... 01, 2014 The annual Social Security cost-of-living ... 2015, says a new forecast by The Senior Citizens ... price index (CPI) data through August, TSCL forecasts that COLAs ... the sixth consecutive year of record low COLAs,” states TSCL ... became automatic in 1975,” he notes. , Over the past ...
Breaking Medicine News(10 mins):Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 2Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 4Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 2Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 4Health News:Indosoft Announces Q-Suite Support For Sangoma Lyra 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3
... , TUESDAY, Jan. 24 (HealthDay News) -- People without ... medical care or prescription drugs than people with jobs who ... the depths of the recent recession, unemployment reached 9.6 percent, ... access to care and most people rely on getting insured ...
... , TUESDAY, Jan. 24 (HealthDay News) -- Children with ... gastroesophageal reflux don,t get additional asthma control from acid-reducing ... these medications when there are no digestive issues increases ... the study. "There,s a strong epidemiological link between ...
... , TUESDAY, Jan. 24 (HealthDay News) -- If you have ... of painful flare-ups, new research suggests. The new study ... in the previous four months. They were divided into three ... or skim milk powder enriched with glycomacropeptide (GMP) and G600 ...
... from Rhode Island Hospital reports on the impact to ... upcoming revision to the Diagnostic and Statistical Manual, 5th ... these changes could result in false-negative diagnoses for patients. ... Clinical Psychiatry and is now available online in ...
... announce that it has entered a new long-term collaboration with ... journal Alcohol and Alcoholism . At the end ... the journal Alcohol and Alcoholism , which was previously ... founded in 1967 to improve the understanding and management of ...
... German . Studies currently available provide ... be detected and treated earlier, and consequently tumours occur less ... In this context, an HPV test can be used alone ... both screening procedures also carry a risk of harm in ...
Cached Medicine News:Health News:Even With Insurance, Unemployed Have Worse Health Outcomes 2Health News:Even With Insurance, Unemployed Have Worse Health Outcomes 3Health News:Heartburn Meds Won't Help, May Harm Kids With Asthma 2Health News:Heartburn Meds Won't Help, May Harm Kids With Asthma 3Health News:Enriched Skim Milk Good for Gout, Study Suggests 2Health News:The impact of deleting 5 personality disorders in the new DSM-5 2Health News:Oxford University Press and Medical Council on Alcohol announce long-term partnership 2Health News:HPV testing: Indications of a benefit in primary screening 2Health News:HPV testing: Indications of a benefit in primary screening 3Health News:HPV testing: Indications of a benefit in primary screening 4
... The National Laboratory Training Network (NLTN) ... Association of Public Health Laboratories (APHL) and ... (CDC). NLTN provides cost-effective training in a ... resources, including a FREE Lending Library. Log ...
... The AAFP-PT Laboratory Proficiency Testing and ... programs are designed to assist POLs, clinics ... are designed to assure accuracy of patient ... regulatory requirements. Participation provides the opportunity to ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) of IgM isotype in human serum....
Medicine Products: